Evidence map›Paper›PMID 31292901›Full record

ArticleCardiology and therapy2019

TRimetazidine as an Agent to affeCt clopidogrEl Response: The TRACER Study.

Naveen Seecheran, Victoria Seebalack, Rajeev Seecheran, Aarti Maharaj, Brent Boodhai, Valmiki Seecheran, Sangeeta Persad, Shastri Motilal, Antonio Tello-Montoliu, David Schneider

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiology and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03603249 (Trimetazidine as an Adjunct to Enhance Clopidogrel Response), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03603249 phase2completednot on this map

Trimetazidine as an Adjunct to Enhance Clopidogrel Response: The TRACER Study.

TypeinterventionalSponsorThe University of The West IndiesRan2018 to 2019Enrolled24ConditionsPlatelet Dysfunction Due to DrugsArmsTrimetazidine
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Naveen SeecheranDepartment of Clinical Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago. Naveen.Seecheran@sta.uwi.edu.ORCID http://orcid.org/0000-0002-7779-0181
Victoria SeebalackDepartment of Clinical Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago.
Rajeev SeecheranDepartment of Medicine, North Central Regional Health Authority, Port of Spain, Trinidad and Tobago.
Aarti MaharajDepartment of Medicine, North Central Regional Health Authority, Port of Spain, Trinidad and Tobago.
Brent BoodhaiDepartment of Medicine, North Central Regional Health Authority, Port of Spain, Trinidad and Tobago.
Valmiki SeecheranDepartment of Medicine, North Central Regional Health Authority, Port of Spain, Trinidad and Tobago.
Sangeeta PersadDepartment of Medicine, North Central Regional Health Authority, Port of Spain, Trinidad and Tobago.
Shastri MotilalDepartment of Clinical Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago.
Antonio Tello-MontoliuDivision of Cardiology, Universidad de Murcia, Murcia, Spain.
David SchneiderCardiovascular Research Institute of Vermont, Colchester, VT, USA.
University of the West Indies · TTUniversidad de Murcia · ES

Funding

Campus Research and Publication Fund from the University of the West Indies, St. Augustine (CRP.4MAR16.38)
6 · The paper itself

Abstract

introductionThis prospective study aimed to determine whether trimetazidine (TMZ) alters the pharmacodynamic (PD) effects of clopidogrel.

methodsPatients with stable coronary artery disease (SCAD) (n = 24) who were actively treated with dual antiplatelet therapy (DAPT) of aspirin 81 mg daily and clopidogrel 75 mg daily were recruited. Platelet function was measured with the VerifyNow P2Y12 assay (Accriva Diagnostics, San Diego, CA, USA) and assessed before the initiation of and after 14 days of treatment with TMZ. Results were compared using a paired t test.

resultsAlmost 80% of the study population were of South Asian descent and had diabetes mellitus (DM). P2Y12 reaction units (PRUs) were higher in patients on TMZ (204 ± 56 compared with 174 ± 71 before TMZ, p = 0.005). The average increase in PRU score was 29 (95% confidence interval 8.8-49.7). Before TMZ, the proportion of patients with high on-treatment platelet reactivity (PRU > 208 units) was 25%, which increased to 42% for patients on TMZ.

conclusionHigher platelet reactivity was seen in patients on TMZ, suggesting that TMZ attenuated the PD effects of clopidogrel in this study of a predominantly South Asian diabetic subpopulation. Alternative therapies should be considered and further research is warranted.

trial registrationClinicalTrials.gov number, NCT03603249.

Indexed as

ClopidogrelPlatelet reactivityTrimetazidine

Identifiers

PMID31292901
PMCPMC6828882
OpenAlexW2959929547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.